

## PUBLIC SUMMARY DOCUMENT

**Product:** Esteem<sup>®</sup> + Flex Convex Drainable

**Applicant:** ConvaTec (Australia) Pty Ltd

**Date of SPAP Meeting:** 11 April 2016

### 1. Proposed Listing on the Stoma Appliance Scheme

The applicant, ConvaTec, sought listing of the Esteem<sup>®</sup> + Flex Convex Drainable One-Piece pouch, in subgroup 2(b) of the Stoma Appliance Scheme (SAS) Schedule. The product including eight variants, was proposed at the unit price of \$6.373 with a maximum monthly quantity of 30 units.

### 2. Comparator

The applicant nominated the ConvaTec Esteem<sup>®</sup> + Convex One-Piece Drainable pouch (SAS code 5699Y) from its own range, which is currently listed in subgroup 2(b), at a unit price of \$6.373 with a maximum monthly quantity of 30 units.

### 3. Background

This was the Stoma Product Assessment Panel (SPAP)'s first consideration of this product.

### 4. Clinical Place for the Product

The proposed product provides an alternative for users requiring a one-piece drainable pouch with convex baseplate.

### 5. SPAP Comment

#### *Clinical Analysis*

The Panel noted that the proposed product is a new version of the currently listed ConvaTec Esteem<sup>®</sup> + Convex One-Piece Drainable (SAS code 5699Y). The Panel noted the difference between the two products is a viewing option.

The Panel agreed that the proposed product is equivalent to products currently available at the benchmark price in subgroup 2(b), therefore listing on a cost minimisation basis was considered appropriate.

#### *Economic Analysis*

Not undertaken.

#### *Financial Analysis*

Listing of this product is recommended on a cost minimisation basis compared with the nominated comparator in subgroup 2(b) of the SAS Schedule. It is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing this product under the conditions requested by the applicant.

### 6. SPAP Recommendation

The SPAP recommended that the ConvaTec Esteem<sup>®</sup> + Convex One-Piece Drainable, including eight variants, be listed in subgroup 2(b) of the SAS Schedule, at a unit price of \$6.373, with a maximum monthly quantity of 30 units.

### 7. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the

SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

**8. Applicant's Comment**

ConvaTec (Australia) Pty Ltd agrees with the SPAP's recommendation contained in the Public Summary Document.